Analyzing Trevena (NASDAQ:TRVN) & Aeolus Pharmaceuticals (NASDAQ:AOLS)
Trevena (NASDAQ:TRVN) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.
This table compares Trevena and Aeolus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Trevena and Aeolus Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Trevena||$5.73 million||14.70||-$30.78 million||($0.42)||-2.17|
|Aeolus Pharmaceuticals||$2.08 million||N/A||-$3.55 million||N/A||N/A|
Aeolus Pharmaceuticals has lower revenue, but higher earnings than Trevena.
Risk and Volatility
Trevena has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 3.18, meaning that its share price is 218% more volatile than the S&P 500.
Institutional and Insider Ownership
22.9% of Trevena shares are held by institutional investors. 3.4% of Trevena shares are held by insiders. Comparatively, 66.6% of Aeolus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current recommendations and price targets for Trevena and Aeolus Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trevena currently has a consensus price target of $6.67, suggesting a potential upside of 632.60%. Given Trevena’s higher probable upside, research analysts clearly believe Trevena is more favorable than Aeolus Pharmaceuticals.
Aeolus Pharmaceuticals beats Trevena on 5 of the 9 factors compared between the two stocks.
Trevena Company Profile
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Aeolus Pharmaceuticals Company Profile
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.